Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Microbix Biosystems Inc

MBX.TO ✓ COMPLIANTFree checks used up today ☆ Track — members

TSE · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: BUY

Last Close

$0.22

▲ +0.00%

Market Cap $30.29M · Vol 4.70K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$30.29M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

44.44

Momentum

Beta

0.55

vs Market

52W High

$0.23

5.40% below

52W Low

$0.15

45.98% above

Volume

4.70K

Avg 31.78K

P/B

1.33

Price-to-book

ROE

N/A

Return on equity

Free Float

84.20%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Microbix Biosystems Inc (MBX.TO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MBX.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.90%

+0.00%

+26.53%

YTD

+34.78%

+29.17%

+3.34%

-47.46%

Financials & Valuation

TTM · Annual

Total Revenue	$13.35M
Net Income	$-1,613,369.00
Revenue Growth (YoY)	+16.91%
Gross Margin	53.02%
Operating Margin	-8.48%
Net Profit Margin	-12.08%
ROE	N/A
ROA · ROIC	-6.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.98
P/B	1.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	136.69M

Technical Indicators

50-Day SMA	$0.22
200-Day SMA	$0.19
RSI (14)	44.44
Beta	0.55
52-Week High	$0.23
52-Week Low	$0.15

Volume Today	4.70K
Avg Daily Volume (30D)	31.78K
Relative Volume	0.15x
Volatility (10D)	50.09
Volatility (30D)	55.59
Free Float	84.20%

Analyst Consensus

BUY

Current Price $0.22

Mean Target $0.29

52W Low$0.15 52W High$0.23

Current

Target

$0.15 $0.23

Current Analyst target

+31.28% upside potential · 0 analysts

Identifiers

ExchangeTSE

FIGIBBG001S6S5C8

ISINCA59501P1045

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateDec 18, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Microbix Biosystems Inc. is a Canada-based company. The Company develops and commercializes proprietary biological and technology solutions for human health and wellbeing. It manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The Company operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.